MedTrace Logo

Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma

NCT04927195 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2022-10-07

No results posted yet for this study

Summary

This Phase 1 study will investigate the safety and tolerability of EDP1867 in healthy volunteers, participants with atopic dermatitis, and, optionally, in participants with psoriasis and/or asthma.

Conditions

Interventions

DRUG

EDP1867

EDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria

DRUG

Placebo

Placebo oral capsule

Sponsors & Collaborators

  • Evelo Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Pui Man Leung, MBChB MRCP FFPM DPM · MAC Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-23
Primary Completion
2022-02-28
Completion
2022-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04927195 on ClinicalTrials.gov